Khusan Khodzhaev
Overview
Explore the profile of Khusan Khodzhaev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Erbilgin Y, Firtina S, Kirat E, Khodzhaev K, Karakas Z, Unuvar A, et al.
Biochem Genet
. 2025 Jan;
PMID: 39786526
IKZF1 deletions (ΔIKZF1) are common in precursor B-cell acute lymphoblastic leukemia (B-ALL) and are assumed to have a prognostic impact. We aimed to determine the prognostic implications of ΔIKZF1 and...
2.
Khodzhaev K, Sudutan T, Erbilgin Y, Saritas M, Yegen G, Bozkurt C, et al.
Eur J Med Genet
. 2024 Sep;
72:104975.
PMID: 39322061
Hodgkin's lymphoma (HL) is the most common cancer in adolescents and young adults. A family history of HL increases the risk of developing HL in other family members. Identification of...
3.
Erbilgin Y, Ng O, Can I, Firtina S, Kucukcankurt F, Karaman S, et al.
Int J Lab Hematol
. 2021 Apr;
43(5):1093-1103.
PMID: 33844466
Introduction: The lymphoid enhancer factor 1 (LEF1) is a DNA-binding transcription factor that functions in the Wnt signaling pathway. Increased LEF1 activity is associated with progression of several types of...
4.
Khodzhaev K, Buyukkapu Bay S, Kebudi R, Altindirek D, Kaya A, Erbilgin Y, et al.
J Clin Immunol
. 2020 Jul;
40(6):883-892.
PMID: 32620996
Genome-wide sequencing studies in pediatric cancer cohorts indicate that about 10% of patients have germline mutations within cancer predisposition genes. Within this group, primary immune deficiencies take the priority regarding...
5.
Erbilgin Y, Eskazan A, Ng O, Salihoglu A, Elverdi T, Firtina S, et al.
Leuk Lymphoma
. 2018 Jul;
60(1):200-207.
PMID: 29965782
Tyrosine kinase inhibitor (TKI) therapy is the current treatment of choice for patients with chronic phase chronic myeloid leukemia (CML) leading to rapid and durable hematological as well as molecular...
6.
Ozkaya H, Comunoglu N, Sayitoglu M, Keskin F, Firtina S, Khodzhaev K, et al.
Pituitary
. 2018 Feb;
21(4):335-346.
PMID: 29455389
Objective: To determine aryl hydrocarbon interacting protein (AIP) gene variations and AIP and somatostatin receptor (SSTR) 1-5 immunostaining in patients with apparently sporadic acromegaly with poor versus good response to...